Nektar Therapeutics Common Stock NKTR
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-12T02:49:34.398Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-12T00:09:23.360918728Z
FundamentalsAlpha Vantage · ready · quarter 2026-06-30 · fetched 2026-11-12T02:40:54.014415+00:00
Nektar Therapeutics Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 33.24 | 123.9% | 15.8% | |||
| 25Δ | 42.81 | 91.8% | 13.5% | 35.06 | 98.1% | 11.2% |
| 30Δ | 41.92 | 92.4% | 11.7% | 35.75 | 105.1% | 10.4% |
| 35Δ | 40.87 | 85.9% | 9.4% | 36.47 | 115.8% | 9.8% |
| 40Δ | 40.10 | 84.3% | 7.9% | |||
| 45Δ | 39.48 | 89.1% | 7.2% | |||
| 50Δ | 38.86 | 94.3% | 6.6% | |||
| 55Δ | 38.14 | 96.8% | 5.8% | 39.59 | 96.2% | 4.6% |
| 60Δ | 37.41 | 97.7% | 4.9% | 40.32 | 92.6% | 3.7% |
| 65Δ | 36.77 | 93.2% | 3.9% | 41.16 | 94.9% | 3.2% |
| 70Δ | 36.26 | 82.8% | 2.8% | 41.85 | 90.9% | 2.4% |
| 75Δ | 35.52 | 81.6% | 2.1% | 42.62 | 88.2% | 1.8% |
| 80Δ | 34.49 | 88.9% | 1.8% | 43.75 | 90.1% | 1.4% |
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 33.24
- IV
- 123.9%
- B/E move
- 15.8%
25Δ
- Pseudo strike
- 42.81
- IV
- 91.8%
- B/E move
- 13.5%
- Pseudo strike
- 35.06
- IV
- 98.1%
- B/E move
- 11.2%
30Δ
- Pseudo strike
- 41.92
- IV
- 92.4%
- B/E move
- 11.7%
- Pseudo strike
- 35.75
- IV
- 105.1%
- B/E move
- 10.4%
35Δ
- Pseudo strike
- 40.87
- IV
- 85.9%
- B/E move
- 9.4%
- Pseudo strike
- 36.47
- IV
- 115.8%
- B/E move
- 9.8%
40Δ
- Pseudo strike
- 40.10
- IV
- 84.3%
- B/E move
- 7.9%
- Pseudo strike
- IV
- B/E move
45Δ
- Pseudo strike
- 39.48
- IV
- 89.1%
- B/E move
- 7.2%
- Pseudo strike
- IV
- B/E move
50Δ
- Pseudo strike
- 38.86
- IV
- 94.3%
- B/E move
- 6.6%
- Pseudo strike
- IV
- B/E move
55Δ
- Pseudo strike
- 38.14
- IV
- 96.8%
- B/E move
- 5.8%
- Pseudo strike
- 39.59
- IV
- 96.2%
- B/E move
- 4.6%
60Δ
- Pseudo strike
- 37.41
- IV
- 97.7%
- B/E move
- 4.9%
- Pseudo strike
- 40.32
- IV
- 92.6%
- B/E move
- 3.7%
65Δ
- Pseudo strike
- 36.77
- IV
- 93.2%
- B/E move
- 3.9%
- Pseudo strike
- 41.16
- IV
- 94.9%
- B/E move
- 3.2%
70Δ
- Pseudo strike
- 36.26
- IV
- 82.8%
- B/E move
- 2.8%
- Pseudo strike
- 41.85
- IV
- 90.9%
- B/E move
- 2.4%
75Δ
- Pseudo strike
- 35.52
- IV
- 81.6%
- B/E move
- 2.1%
- Pseudo strike
- 42.62
- IV
- 88.2%
- B/E move
- 1.8%
80Δ
- Pseudo strike
- 34.49
- IV
- 88.9%
- B/E move
- 1.8%
- Pseudo strike
- 43.75
- IV
- 90.1%
- B/E move
- 1.4%
Options history
Table
| Date | IV (%) |
|---|---|
| 75.88% | |
| 73.38% | |
| 75.43% | |
| 76.07% | |
| 69.80% | |
| 76.91% | |
| 73.81% | |
| 73.87% | |
| 73.72% | |
| 76.08% |
Biotechnology
NKTX
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and markets cell therapies for the treatment of cancer. The company is headquartered in South San Francisco,…
More →NMRA
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and…
More →NRIX
Description unavailable
More →NRXP
Description unavailable
More →NRXS
NeurAxis, Inc. is a neuromodulation therapy device company in the United States. The company is headquartered in Versailles, Indiana.
More →NTLA
Intellia Therapeutics, Inc., a genome editing company, is focused on developing therapies. The company is headquartered in Cambridge, Massachusetts.
More →